wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38404422-AA1F3FA4-1C4D-41FC-978A-F3DEF2E6B051
Q38404422-AA1F3FA4-1C4D-41FC-978A-F3DEF2E6B051
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38404422-AA1F3FA4-1C4D-41FC-978A-F3DEF2E6B051
Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?
P2860
Q38404422-AA1F3FA4-1C4D-41FC-978A-F3DEF2E6B051
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38404422-AA1F3FA4-1C4D-41FC-978A-F3DEF2E6B051
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
38c4135fe57d9f81540a31d707b3606ba694db31
P2860
Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion